 |
|
|
|
|
|
 Title: |
US5068175:
Method of detecting ras oncogene related malignancies
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Prashad, Nagindra; Houston, TX
|
| Assignee: |
Board of Regents, The University of Texas Sysem, Austin, TX
other patents from UNIVERSITY OF TEXAS (600015) (approx. 1,442)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1991-11-26
/ 1989-05-26
|
| Application Number: |
US1989000358449
|
| IPC Code: |
Advanced:
C12Q 1/68;
G01N 33/574;
Core:
more...
IPC-7:
C07H 15/12;
C12N 15/00;
C12Q 1/68;
G01N 33/48;
|
| U.S. Class: |
Current:
435/006;
435/005;
436/064;
436/813;
530/406;
536/024.3;
536/024.31;
Original:
435/006;
536/027;
935/077;
935/078;
530/406;
436/064;
436/813;
|
| Field of Search: |
435/006
536/027
935/077,78
530/406
436/813,64
|
| Priority Number: |
| 1989-05-26 |
US1989000358449 |
|
| Abstract: |
Methods and composition for detecting the presence of human ras oncogene related malignancies are provided, where a biological sample is assayed for protein(s) specific to a DNA sequence. In the methods of this invention, the test reaction involves admixing a biological sample from cancer patients or control donors with labelled ras oncogene promoter DNA. The admixture is incubated under conditions favorable for promoting specific interactions between proteins and the labelled DNA. Thereafter, the admixture is separated by charge and size in an electrophoretic field and the protein-DNA interactions are identified depending on the method of label employed. Bands migrating at a slower rate than the uncomplexed DNA are indicative of a protein-DNA interaction (i.e. circulating serum protein(s) from cancer patients interacting specifically with a region(s) of the ras oncogene promoter DNA). Utilizing this experimental protocol, the serum proteins of interest include at least four different proteins that specifically interact with a region or regions of the ras oncogene promoter DNA. The four different factors, ranging in molecular weight from about 200 Kd to about 50 Kd are proteinaceous in nature as demonstrated by their trypsin sensitivity and heat stability.
|
| Attorney, Agent or Firm: |
Arnold, White & Durkee ;
|
| Primary / Asst. Examiners: |
Nucker, Christine; Fleisher, Mindy B.
|
| INPADOC Legal Status: |
Show legal status actions
|
| Family: |
None
|
First Claim:
Show all 16 claims |
What is claimed is:
1. A method for detecting ras oncogene related malignancy in a human subject, comprising the steps of:
- a) collecting a test serum or plasma sample from a human subject;
- b) providing a control serum or plasma sample from a tumor free donor;
- c) incubating each of the control and test samples with a DNA having a sequence consisting essentially of a human ras oncogene promoter under conditions effective to promote specific binding interactions between protein factors in the samples and the DNA sequence;
- d) separating in each of the control and test samples a protein factor-DNA complex from free DNA; and
- e) comparing the amounts of protein factor-DNA complex of both the test and control samples, wherein if the test sample features an amount of about 10-fold or higher of a protein factor-DNA complex than the control sample, there is an indication of a ras oncogene related malignancy.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 11 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
None
|
| Other References: |
Maniatis et al., Molecular Cloning-A Laboratory Manual, 1982, Cold Spring Harbor Laboratory, p. 151.
Ashii et al., Science, vol. 232, pp. 1410-1413 (1986).
C. J. Der et al., "Altered gene products are associated with activation of cellular ras genes in human lung and colon carcinomas," Cell 32:201-08 (1983).
L. A. Feig et al., "Somatic activation of ras gene in human ovarian carcinoma," Science 223:698-700 (1984).
(3 pages)
Cited by 15 patents
M. S. McCoy et al., "Characterization of a human colon/lung carcinoma oncogene," Nature 302:79-81 (1983).
(3 pages)
M. V. Viola et al., "Expression of ras oncogene p21 in prostate cancer," New Eng. J. of Med. 314:133-137 (1986).
(5 pages)
Cited by 2 patents
S. Ishii et al., "Binding of the Spl transcription factor by the human Harvey rasl proto-oncogene promoter," Science 232:1410-1413 (1986).
(4 pages)
H. Dosaka et al., "Immunohistochemical analysis of human lung cancers with anti-ras p21 monoclonal antibodies," Int. J. Biol. Markers 2(2):75-82 (1987).
P. Garrett et al., "Clinical utility of oncofetal proteins and hormones as tumor markers," Medical Clinics of N. Am. 70(b):1295-1306 (1986).
(12 pages)
B. Czerniak et al., "ras oncogene p21 as a tumor marker in the cytodiagnosis of gastric and colonic carcinomas," Cancer 60:2432-2436 (1987).
(5 pages)
L. M. Stock et al., "ras related oncogene protein as a tumor marker in transitional cell carcinoma of the bladder," J. of Urol. 137(4):789-792 (1987).
(4 pages)
H. Honkawa et al., "Identification of the principal promoter sequence of the C-H-ras transforming oncogene: deletional analysis of the 5'-flanking region by focus formation," Mol. Cell. Biol. 7(8):2933-2940 (1987).
(8 pages)
M. G. Borrello et al., "Modulation of the human Harvey-ras oncogene expression by DNA methylation," Oncogene Res. 2(2):197-203 (1988).
(7 pages)
S. Ishii et al., "Promoter region of the human Harvey ras proto-oncogene: Similarity to the EGF receptor proto-oncogene promoter," Science 230(47 32):1378-1381 (1985).
(4 pages)
G. E. Gallick et al., "Expression of p21 ras in fresh primary and mestastic human colorectal tumors," Proc. Natl. Acad. Sci. 82:1795-1799 (1985).
(5 pages)
Cited by 7 patents
J. L. Bos et al., "Prevalence of ras gene mutations in human colorectal cancers," Nature 327:293-297 (1987).
(5 pages)
Cited by 48 patents
|
|
 Nominate this for the Gallery...
|
|
